New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely on viral vectors.

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

Our strategic approach is about advancing science to benefit patients most in need of new therapies. As a private company led by a non-profit foundation, Servier is uniquely positioned to make ...